Cholesteryl ester transfer protein inhibitors: challenges and perspectives

References

• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610.
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Kei AA, Filippatos TD, Elisaf MS. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opin Drug Saf. 2016;15:559–569.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Statin-ezetimibe combination therapy in diabetic individuals. Angiology. 2016;67:507–509.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273–274.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT: opinions of three experts - III. Hellenic J Cardiol. 2015;56:7–9.
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310.
   PubMed Web of Science ®Google Scholar
• Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids. 2006;41:647–654.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Gazi I, Filippatos T, et al. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis. 2010;208:506–511.
   PubMed Web of Science ®Google Scholar
• Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Ather Suppl. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–361.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945–1958.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14:1481–1493.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Kosmas CE, DeJesus E, Rosario D, et al. CETP inhibition: Past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37–42.
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255–1274.
   PubMed Web of Science ®Google Scholar
• Ikewaki K, Mabuchi H, Teramoto T, et al. Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects. Metabolism. 2003;52:1564–1570.
   PubMed Web of Science ®Google Scholar
• Lewis-Barned NJ, Sutherland WH, Walker RJ, et al. Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women. J Clin Endocrinol Metab. 1999;84:3534–3538.
   PubMed Web of Science ®Google Scholar
• Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 1995;15:1819–1828.
   PubMed Web of Science ®Google Scholar
• Beentjes JA, Van Tol A, Sluiter WJ, et al. Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy. Scand J Clin Lab Invest. 2000;60:189–198.
   PubMed Web of Science ®Google Scholar
• Inazu A, Jiang XC, Haraki T, et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 1994;94:1872–1882.
   PubMed Web of Science ®Google Scholar
• Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985;58:175–186.
   PubMed Web of Science ®Google Scholar
• Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. Jama. 2008;299:2777–2788.
   PubMed Web of Science ®Google Scholar
• Johannsen TH, Frikke-Schmidt R, Schou J, et al. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60:2041–2048.
   PubMed Web of Science ®Google Scholar
• Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45:948–953.
   PubMed Web of Science ®Google Scholar
• Okamura T, Sekikawa A, Kadowaki T, et al. Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men. Am J Cardiol. 2009;104:818–822.
   PubMed Web of Science ®Google Scholar
• Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29:2792–2799.
   PubMed Web of Science ®Google Scholar
• Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab. 2006;91:3382–3388.
   PubMed Web of Science ®Google Scholar
• Borggreve SE, Hillege HL, Dallinga-Thie GM, et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J. 2007;28:1012–1018.
   PubMed Web of Science ®Google Scholar
• Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917–2923.
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–1515.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–1630.
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–160.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
   PubMed Web of Science ®Google Scholar
• Robinson JG. Dalcetrapib: a review of phase II data. Expert Opin Investig Drugs. 2010;19:795–805.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Miller M, Niesor EJ, et al. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012;163:515–521,521 e511–513.
   PubMed Web of Science ®Google Scholar
• Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J. 2010;31:480–488.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
   PubMed Web of Science ®Google Scholar
• Ip CK, Jin DM, Gao JJ, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138–148.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Rheaume E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015;8:372–382.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendia LE, Guerrero-Romero F, et al. Efficacy and safety of evacetrapib for modifying plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2016;22:595–608.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Barter PJ, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial. Am Heart J. 2015;170:1061–1069.
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907–1914.
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–360 e352.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
   PubMed Web of Science ®Google Scholar
• Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. 2016;126:1603–1604.
   PubMed Web of Science ®Google Scholar
• Dong B, Singh AB, Fung C, et al. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014;235:449–462.
   PubMed Web of Science ®Google Scholar
• Brinton EA, Kher U, Shah S, et al. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (determining the efficacy and tolerability of CETP inhibition with AnacEtrapib) trial. J Clin Lipidol. 2015;9:65–71.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr., Kher U, Chatterjee MS, et al. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther. 2014;19:543–549.
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr., Cannon CP, Li XS, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113:76–83.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Kastelein JJ, Van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452–460.
   PubMed Web of Science ®Google Scholar
• Barter P. Lessons learned from the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Am J Cardiol. 2009;104:10E–15E.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosis by CETP inhibition and HDL elevation). Circulation. 2008;118:2506–2514.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–1138.
   PubMed Web of Science ®Google Scholar
• Ray KK, Ditmarsch M, Kallend D, et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014;35:1792–1800.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol. 2015;66:2201–2210.
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30:1430–1438.
   PubMed Web of Science ®Google Scholar
• Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507–513.
   PubMed Web of Science ®Google Scholar
• Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–2393.
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, De La Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–135.
   PubMed Web of Science ®Google Scholar
• Maugeais C, Perez A, Von Der Mark E, et al. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP. Biochim Biophys Acta. 2013;1831:1644–1650.
   PubMed Web of Science ®Google Scholar
• Briand F, Thieblemont Q, Andre A, et al. CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice. Clin Transl Sci. 2011;4:414–420.
   PubMed Web of Science ®Google Scholar
• Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–3454.
   PubMed Web of Science ®Google Scholar
• Briand F, Thieblemont Q, Muzotte E, et al. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arterioscler Thromb Vasc Biol. 2013;33:13–23.
   PubMed Web of Science ®Google Scholar
• Tchoua U, D’Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77:732–739.
   PubMed Web of Science ®Google Scholar
• Castro-Perez J, Briand F, Gagen K, et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res. 2011;52:1965–1973.
   PubMed Web of Science ®Google Scholar
• Briand F, Thieblemont Q, Muzotte E, et al. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. Eur J Pharmacol. 2014;740:135–143.
   PubMed Web of Science ®Google Scholar
• Annema W, Tietge UJ. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond). 2012;9:25.
   PubMed Web of Science ®Google Scholar
• Kosmas CE, Christodoulidis G, Cheng JW, et al. High-density lipoprotein functionality in coronary artery disease. Am J Med Sci. 2014;347:504–508.
   PubMed Web of Science ®Google Scholar
• Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17:594–603.
   PubMed Web of Science ®Google Scholar
• Ishigami M, Yamashita S, Sakai N, et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem. 1994;116:257–262.
   PubMed Web of Science ®Google Scholar
• Kontush A. HDL particle number and size as predictors of cardiovascular disease. Front Pharmacol. 2015;6:218.
   PubMed Web of Science ®Google Scholar
• Rashedi N, Brennan D, Kastelein JJ, et al. Impact of cholesteryl ester transfer protein inhibition on nuclear magnetic resonance derived lipoprotein particle prameters (abstract). Ather Suppl. 2011;12:48.
   Web of Science ®Google Scholar
• Sloop GD, Weidman JJ, St Cyr JA. Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity? Ther Adv Cardiovasc Dis. 2015;9:32–35.
   PubMedGoogle Scholar
• Van Der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634–642.
   PubMed Web of Science ®Google Scholar
• Clerc RG, Stauffer A, Weibel F, et al. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J Hypertens. 2010;28:1676–1686.
   PubMed Web of Science ®Google Scholar
• Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009;150:2211–2219.
   PubMed Web of Science ®Google Scholar
• Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465–1473.
   PubMed Web of Science ®Google Scholar
• Rios FJ, Neves KB, Nguyen Dinh Cat A, et al. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. J Pharmacol Exp Ther. 2015;353:27–34.
   PubMed Web of Science ®Google Scholar
• Connelly MA, Parry TJ, Giardino EC, et al. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol. 2010;55:459–468.
   PubMed Web of Science ®Google Scholar
• Simic B, Hermann M, Shaw SG, et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J. 2012;33:1615–1624.
   PubMed Web of Science ®Google Scholar
• Rios F, Alves R, Neves K, et al. Off-target vascular effects of cholesteryl ester transfer protein (CETP) inhibitors involve redox-sensitive and STAT3-dependent pathways. J Pharmacol Exp Ther. 2016;357:415–422.
   PubMed Web of Science ®Google Scholar
• Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44:2301–2306.
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Filippatos TD, Loukas T, et al. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis. 2006;187:170–176.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–477.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye K-A, Tardif J-C, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Circulation. 2011;124:555–562.
   PubMed Web of Science ®Google Scholar
• Siebel AL, Natoli AK, Yap FY, et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res. 2013;113:167–175.
   PubMed Web of Science ®Google Scholar
• Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56:2328–2338.
   PubMed Web of Science ®Google Scholar
• Nair DR, Sharifi M, Al-Rasadi K. Familial hypercholesterolaemia. Curr Opin Cardiol. 2014;29:381–388.
   PubMed Web of Science ®Google Scholar
• deGoma EM, Ahmad ZS, O’Brien EC, et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. Circ Cardiovasc Genet. 2016. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• De Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis. 2004;173:261–267.
   PubMed Web of Science ®Google Scholar
• Holmes DT, Schick BA, Humphries KH, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005;51:2067–2073.
   PubMed Web of Science ®Google Scholar